(Q37766531)

22 August 2017

1 reference

title

Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas (English)

1 reference

22 August 2017

1 reference

Marc C Chamberlain

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

116

1 reference

22 August 2017

issue

17

1 reference

22 August 2017

page(s)

3988-3999

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

VEGF as a therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Angiogenesis in brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Microvessel density is a prognostic indicator for patients with astroglial brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

A perivascular niche for brain tumor stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Salvage therapy with single agent bevacizumab for recurrent glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Bevacizumab plus irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Spontaneous intracranial hemorrhage caused by brain tumor: its incidence and clinical significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Epidemiology of venous thromboembolism in 9489 patients with malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Irinotecan therapy in adults with recurrent or progressive malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Safety of anticoagulation use and bevacizumab in patients with glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Taming glioblastoma: targeting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Surrogate markers in antiangiogenesis clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Effect of bevacizumab on radiation necrosis of the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Brain edema in neurooncology: radiological assessment and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Patterns of care for adults with newly diagnosed malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Emerging antiangiogenic treatments for gliomas - efficacy and safety issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Novel anti-angiogenic therapies for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Bevacizumab reverses cerebral radiation necrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Bevacizumab for recurrent ependymoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Bevacizumab and irinotecan for recurrent oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Paraoxonase genes and susceptibility to ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

inferred from DOI database lookup

7 January 2021

based on heuristic

Spontaneous intracranial haematomas caused by neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25256

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.25256

1 reference

22 August 2017

1 reference